Analgesia After Cesarean Section

This study has been completed.

Sponsor:

Information provided by:

Seoul National University Bundang Hospital

ClinicalTrials.gov Identifier:

NCT01360060

First received: May 17, 2011

Last updated: May 24, 2011

Last verified: May 2011

History of Changes

Tracking Information
First Received Date ^ICMJE	May 17, 2011
Last Updated Date	May 24, 2011
Start Date ^ICMJE	December 2010
Primary Completion Date	March 2011 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: May 24, 2011)	Change of numeric rating scale (NRS) of postoperative pain during postoperative period [ Time Frame: postoperative 1, 2, 3, and 4 day ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT01360060 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: May 24, 2011)	incidence of stopping of intravenous PCA during postoperative 4 days [ Time Frame: during postoperative 4 days ] [ Designated as safety issue: No ] serum magnesium level of group P [ Time Frame: preoperative 1 h and postoperative 1 day ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Analgesia After Cesarean Section
Official Title ^ICMJE	Not Provided
Brief Summary	Magnesium sulphate is the first line therapy for the management of preeclampsia and eclampsia in obstetrics. Perioperative administration of magnesium sulphate has been proved to be an effective as an analgesic adjuvant. The investigators evaluated the analgesic effect of magnesium in parturients undergoing Cesarean section.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Case Control Time Perspective: Retrospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	medical record review
Condition ^ICMJE	Preeclampsia Pregnancy
Intervention ^ICMJE	Drug: Magnesium Sulphate Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
Study Group/Cohort (s)	Group N parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia Group P parturients who had undergone Cesarean section under the diagnosis of preeclampsia Intervention: Drug: Magnesium Sulphate
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	503
Completion Date	March 2011
Primary Completion Date	March 2011 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: parturients undergoing Cesarean section
Gender	Female
Ages	20 Years to 50 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Korea, Republic of

Administrative Information
NCT Number ^ICMJE	NCT01360060
Other Study ID Numbers ^ICMJE	Mg_section
Has Data Monitoring Committee	Not Provided
Responsible Party	Hyoseok, Na/professor, Seoul National University Bundang Hospital
Study Sponsor ^ICMJE	Seoul National University Bundang Hospital
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Seoul National University Bundang Hospital
Verification Date	May 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top